Fulcrum therapeutics announces recent business highlights and financial results for fourth quarter and full year 2023

― on track to report topline data for phase 3 reach trial of losmapimod in facioscapulohumeral m uscular dystrophy (fshd) in the fourth quarter of 2024 ―

FULC Ratings Summary

FULC Quant Ranking